Alzheimer’s disease: pathogenesis, diagnostics, and therapeutics

Alzheimer’s disease: pathogenesis, diagnostics, and therapeutics

Sneham Tiwari, Venkata Atluri, Ajeet Kaushik, Adriana Yndart, Madhavan NairDepartment of Immunology and Nano-Medicine, Institute of NeuroImmune Pharmacology, Herbert Wertheim College of Medicine, Florida International University, Miami, FL 33199, USAAbstract: Currently, 47 million people live with d...

Full description

Bibliographic Details
Main Authors:	Tiwari S, Atluri V, Kaushik A, Yndart A, Nair M
Format:	Article
Language:	English
Published:	Dove Medical Press 2019-07-01
Series:	International Journal of Nanomedicine
Subjects:	Amyloid Beta Amyloidogenesis Amyloid precursor proteins β-secretase gamma-secretase Tau phosphorylation
Online Access:	https://www.dovepress.com/alzheimerrsquos-disease-pathogenesis-diagnostics-and-therapeutics-peer-reviewed-article-IJN

Similar Items

Cholesterol-dependent amyloid β production: space for multifarious interactions between amyloid precursor protein, secretases, and cholesterol
by: Vladimir Rudajev, et al.
Published: (2023-09-01)

Expression of Amyloid Precursor Protein, Caveolin-1, Alpha-, Beta-, and Gamma-Secretases in Penumbra Cells after Photothrombotic Stroke and Evaluation of Neuroprotective Effect of Secretase and Caveolin-1 Inhibitors
by: Svetlana Sharifulina, et al.
Published: (2022-10-01)

Alzheimer’s Disease: Background, Current and Future Treatments
by: Evelyn Chou
Published: (2014-06-01)

Constitutive α- and β-secretase cleavages of the amyloid precursor protein are partially coupled in neurons, but not in frequently used cell lines
by: Alessio Colombo, et al.
Published: (2013-01-01)

Gamma-secretase modulators: a promising route for the treatment of Alzheimer's disease
by: Gunnar Nordvall, et al.
Published: (2023-10-01)

Alzheimer’s Disease: Current and Future Treatments. A Review
by: Evelyn Chou
Published: (2014-05-01)

Soluble Gamma-secretase Modulators Attenuate Alzheimer's β-amyloid Pathology and Induce Conformational Changes in Presenilin 1
by: Frank Raven, et al.
Published: (2017-10-01)

Using the Zebrafish model for Alzheimer’s Disease Research
by: Morgan eNewman, et al.
Published: (2014-06-01)

Krüppel-like factor 5 accelerates the pathogenesis of Alzheimer’s disease via BACE1-mediated APP processing
by: Yaqi Wang, et al.
Published: (2022-07-01)

Relationship between ubiquilin-1 and BACE1 in human Alzheimer's disease and APdE9 transgenic mouse brain and cell-based models
by: Teemu Natunen, et al.
Published: (2016-01-01)

Cellular basis of Alzheimer′s disease
by: Bali Jitin, et al.
Published: (2010-10-01)

Brain Ischemia as a Prelude to Alzheimer's Disease
by: Ryszard Pluta, et al.
Published: (2021-02-01)

Decreased Deposition of Beta-Amyloid 1-38 and Increased Deposition of Beta-Amyloid 1-42 in Brain Tissue of Presenilin-1 E280A Familial Alzheimer’s Disease Patients
by: Felix Dinkel, et al.
Published: (2020-07-01)

Targeting Amyloidogenic Processing of APP in Alzheimer’s Disease
by: Jing Zhao, et al.
Published: (2020-08-01)

Association of the Protein-Quality-Control Protein Ubiquilin-1 With Alzheimer’s Disease Both in vitro and in vivo
by: Can Zhang, et al.
Published: (2022-03-01)

The Large Ectodomain of APP Prevents APP from being Directly Cleaved by γ-Secretase
by: Yuan Li, et al.
Published: (2024-02-01)

Abeta(1–40)-induced secretion of matrix metalloproteinase-9 results in sAPPα release by association with cell surface APP
by: Argiris A. Talamagas, et al.
Published: (2007-12-01)

Matriptase cleaves the amyloid-beta peptide 1–42 at Arg-5, Lys-16, and Lys-28
by: Li-Mei Chen, et al.
Published: (2019-01-01)

The amyloid-beta forming tripeptide cleavage mechanism of γ-secretase
by: David M Bolduc, et al.
Published: (2016-08-01)

Effect of Eight Weeks of Positive Slope and Negative Slope Training, Along with Royal Jelly on The Hippocampal Expression Of Β- Amyloid And Γ-Secretase in Trimethyltin-Induced Alzheimer's Disease Rats
by: Zahra Giti, et al.
Published: (2021-01-01)

Homer2 and Homer3 interact with amyloid precursor protein and inhibit Aβ production
by: Loukia Parisiadou, et al.
Published: (2008-06-01)

Participation of Amyloid and Tau Protein in Post-Ischemic Neurodegeneration of the Hippocampus of a Nature Identical to Alzheimer's Disease
by: Ryszard Pluta, et al.
Published: (2021-02-01)

HSV-1 and Alzheimer’s Disease: more than a hypothesis
by: Roberto ePiacentini, et al.
Published: (2014-05-01)

Specific Mutations near the Amyloid Precursor Protein Cleavage Site Increase γ-Secretase Sensitivity and Modulate Amyloid-β Production
by: Ryota Suzuki, et al.
Published: (2023-02-01)

Late-long-term potentiation magnitude, but not Aβ levels and amyloid pathology, is associated with behavioral performance in a rat knock-in model of Alzheimer disease
by: Metin Yesiltepe, et al.
Published: (2022-11-01)

Potential preventive disease-modifying pharmacological strategies to delay late onset Alzheimer's disease
by: Miren Ettcheto, et al.
Published: (2019-01-01)

Secretases Related to Amyloid Precursor Protein Processing
by: Xiaoling Liu, et al.
Published: (2021-12-01)

Discovery of Compounds That Selectively Repress the Amyloidogenic Processing of the Amyloid Precursor Protein: Design, Synthesis and Pharmacological Evaluation of Diphenylpyrazoles
by: Christophe Mesangeau, et al.
Published: (2022-10-01)

Emerging Alternative Proteinases in APP Metabolism and Alzheimer’s Disease Pathogenesis: A Focus on MT1-MMP and MT5-MMP
by: Laura García-González, et al.
Published: (2019-09-01)

Molecular mechanism of the intramembrane cleavage of the β-carboxyl terminal fragment of amyloid precursor protein by γ-secretase
by: Maho eMorishima-Kawashima
Published: (2014-11-01)

Conformational Changes and Unfolding of β-Amyloid Substrates in the Active Site of γ-Secretase
by: Jakub Jakowiecki, et al.
Published: (2024-02-01)

Macroalgae as a Valuable Source of Naturally Occurring Bioactive Compounds for the Treatment of Alzheimer’s Disease
by: Tosin A. Olasehinde, et al.
Published: (2019-10-01)

Piceatannol, a natural analogue of resveratrol, effectively reduces beta-amyloid levels via activation of alpha-secretase and matrix metalloproteinase-9
by: Boyoung Choi, et al.
Published: (2016-05-01)

BACE-1 and γ-Secretase as Therapeutic Targets for Alzheimer’s Disease
by: Miguel A. Maia, et al.
Published: (2019-03-01)

BACE1 Function and Inhibition: Implications of Intervention in the Amyloid Pathway of Alzheimer’s Disease Pathology
by: Gerald Koelsch
Published: (2017-10-01)

Scaffold Morphing and In Silico Design of Potential BACE-1 (β-Secretase) Inhibitors: A Hope for a Newer Dawn in Anti-Alzheimer Therapeutics
by: Shiveena Bhatia, et al.
Published: (2023-08-01)

Neurotoxic effects induced by the Drosophila amyloid-β peptide suggest a conserved toxic function
by: Katia Carmine-Simmen, et al.
Published: (2009-02-01)

Potential Implications of miRNAs in the Pathogenesis, Diagnosis, and Therapeutics of Alzheimer’s Disease
by: Long Wang, et al.
Published: (2023-11-01)

Beta-Secretase 1 Recruits Amyloid-Beta Precursor Protein to ROCK2 Kinase, Resulting in Erroneous Phosphorylation and Beta-Amyloid Plaque Formation
by: István Hajdú, et al.
Published: (2023-06-01)

he amyloid hypothesis of Alzheimer's disease: past and present, hopes and disappointments
by: I. V. Litvinenko, et al.
Published: (2019-11-01)